Interferon-α (IFN-α), the former standard treatment for chronic hepatitis C viral (HCV) infection, predisposed patients to a significant risk of major depressive side effects (IFN-α-induced depression), with incidence rates from 23% to 45% [1]. This evidence concerns the gene IFNA17 and depressive symptom measurement.